查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1601240

進行性遺傳性肝內膽汁淤積治療市場：按藥物類型、分銷管道、最終用戶分類 - 全球預測 2025-2030

Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，進行性遺傳性肝內膽汁淤積治療市場估值為1.1352億美元，預計到2024年將達到1.1862億美元，複合年成長率為4.65%，到2030年預計將達到1.5614億美元。

進行性遺傳性肝內膽汁淤積 (PFIC) 是一組罕見的遺傳性肝損傷，其特徵是膽汁流動受損（膽汁淤積），可導致肝損傷。 PFIC 的治療涉及基因治療和藥物開發等新型干涉措施，以控制症狀、改善肝功能並開發具有治癒潛力的有效治療方法。 PFIC 治療工作的必要性強調了預防嚴重肝損傷和改善受影響患者的生活品質的潛力。最終用途主要是醫院、專科診所和研究機構。

主要市場統計
基準年[2023] 11352萬美元
預測年份 [2024] 11862萬美元
預測年份 [2030] 1.5614億美元
複合年成長率（%） 4.65%

PFIC 治療市場受到成長要素的影響，例如對罕見疾病的認知不斷提高、基因研究的進步以及醫療保健支出的增加。隨著公司專注於基因療法和新型小分子藥物等創新治療方案，鼓勵新科學發現和罕見疾病研究的法律規範正在創造潛在的治療機會。為了利用這些機會，相關人員應投資與學術機構的合作夥伴關係進行合作研究，並利用政府對孤兒藥開發的獎勵。

然而，市場開拓面臨研發成本高、新興市場罕見疾病臨床試驗複雜、盛行率低導致病患招募面臨挑戰等限制。鑑於在小型患者群體中證明療效的嚴格指導方針，探索監管途徑也很困難。

在技​​術創新方面，最好的領域包括CRISPR等基因編輯技術以及用於早期診斷的生物標記的開發。此外，人工智慧主導的分析有可能徹底改變患者資料分析和試驗最佳化。 PFIC 治療市場本質上是利基市場，但具有快速成長的潛力。製藥公司、研究人員和醫療保健提供者之間持續透明的合作對於促進創新和有效解決未滿足的醫療需求至關重要。

市場動態：快速發展的進行性遺傳性肝內膽汁淤積治療市場的關鍵市場洞察

供需的動態交互作用正在改變進行性的遺傳性肝內膽汁淤積治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 由於醫療基礎設施的改善，對進行性遺傳性肝內膽汁淤積症的檢測增加
    • 擴大患者支持組織的角色以擴大 PFIC 治療
  • 市場限制因素
    • 獲得 PFIC 治療和治療費用問題
  • 市場機會
    • PFIC 研究和診斷技術的進展
    • 政府對 PFIC 治療的有利核准
  • 市場挑戰
    • PFIC 疾病管理和治療效果的複雜性

波特五力：引領進行性遺傳性肝內膽汁淤積治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解進行性遺傳性肝內膽汁淤積治療市場的外在影響

外部宏觀環境因素在塑造進行性遺傳性肝內膽汁淤積治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解進行性遺傳性肝內膽汁淤積治療市場的競爭格局

進行性遺傳性肝內膽汁淤積治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣進行性遺傳性性肝內膽汁淤積治療市場供應商的績效評估

FPNV定位矩陣是評估進行進行性遺傳性肝內膽汁淤積治療市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 改善的醫療基礎設施增加了進行性遺傳性肝內膽汁淤積症的檢測
      • 擴大患者權益團體的角色以擴大 PFIC 治療
    • 抑制因素
      • 獲得 PFIC 治療和費用負擔問題
    • 機會
      • PFIC 研究和診斷技術的進展
      • 政府對 PFIC 治療的有利核准
    • 任務
      • PFIC 疾病管理和治療效果的複雜性
  • 市場區隔分析
    • 藥物類型：增加考來烯胺的使用以降低肝臟和血液中膽汁酸的濃度
    • 通路：首選網路藥局，永續且方便地取得處方藥。
    • 最終使用者：PFIC 治療可能在醫院進行，以處理 PFIC 的嚴重併發症
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章進行性遺傳性肝內膽汁淤積治療市場：依藥物類型

  • 消膽胺
  • 利福平
  • 熊去氧膽酸

第7章進行性遺傳性肝內膽汁淤積治療市場：依通路

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第8章進行性遺傳性肝內膽汁淤積治療市場：依最終用戶

  • 門診手術中心
  • 醫院
  • 專科診所

第9章北美與南美遺傳性肝內膽汁淤積症治療市場的進行性

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區進行性遺傳性肝內膽汁淤積治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲進行性遺傳性肝內膽汁淤積治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • FDA核准Livmarli 用於治療進行進行性遺傳性肝內膽汁淤積症患者的搔癢症
    • 加拿大政府將撥款 2,000 萬加元，用於改善患有罕見疾病（包括進行性遺傳性肝內膽汁淤積症）的兒童的健康狀況。
    • 法國政府向 Vivet Therapeutics 授予 490 萬歐元津貼，用於創新基因療法的開發
    • 加拿大衛生署核准Bylvay (odevixibat) 治療 PFIC 相關搔癢
    • 北康成藥 CAN108 NDA 獲 NMPA核准
    • UKRI 投入 1400 萬英鎊進一步研究進行進行性遺傳性肝內膽汁淤積症和其他罕見疾病
    • Jadeite Medicines 在日本透過 3 期研究和孤兒藥資格認定推進 PFIC 的治療
    • 印度已撥款4億印度盧比用於加強罕見疾病的治療，並專注於加強PFIC和患者照護。
    • Ipsen 透過策略收購 Albireo Pharma 加強其罕見疾病藥物供應

公司名單

  • AbbVie, Inc.
  • Calliditas Therapeutics AB
  • CANbridge Pharmaceuticals Inc.
  • Centurion Laboratories Private Limited
  • CymaBay Therapeutics, Inc.
  • Enomark
  • Glenmark Pharmaceuticals Limited
  • Healthy Life Pharma Pvt. Ltd.
  • Hebei Xingang Pharmaceutical Co., Ltd.
  • Intercept Pharmaceuticals, Inc.
  • Ipsen Pharma
  • Jackson Laboratories Pvt Ltd.
  • Macleods Pharmaceuticals Ltd.
  • Mirum Pharmaceuticals, Inc.
  • Novartis AG
  • Par Pharmaceuticals, Inc. by Endo International PLC
  • Pfizer Inc.
  • Sanofi SA
  • SiNi Pharma Pvt. Ltd.
  • Taj Pharmaceuticals Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Vivet Therapeutics
  • Wellona Pharma
  • Zoic Biotech Pvt. Ltd.
Product Code: MRR-AD517FAAA5F2

The Progressive Familial Intrahepatic Cholestasis Treatment Market was valued at USD 113.52 million in 2023, expected to reach USD 118.62 million in 2024, and is projected to grow at a CAGR of 4.65%, to USD 156.14 million by 2030.

Progressive Familial Intrahepatic Cholestasis (PFIC) represents a group of rare genetic liver disorders characterized by impaired bile flow (cholestasis), which can lead to liver damage. The scope of PFIC treatment involves developing effective therapies to manage symptoms, improve liver function, and potentially cure the disease through novel interventions such as gene therapy and drug development. The necessity of addressing PFIC treatment is underscored by its potential to prevent severe liver damage and improve life quality for affected patients, often necessitating liver transplantation in severe cases. Applications span from pharmaceutical development to advanced diagnostic tools, while the end-use scope primarily includes hospitals, specialty clinics, and research institutions.

KEY MARKET STATISTICS
Base Year [2023] USD 113.52 million
Estimated Year [2024] USD 118.62 million
Forecast Year [2030] USD 156.14 million
CAGR (%) 4.65%

The PFIC treatment market is influenced by growth factors such as increasing awareness of rare diseases, advancements in genetic research, and a rise in healthcare expenditure. Opportunities are emerging as companies focus on innovative treatment options like gene therapies and novel small-molecule drugs, which hold potential due to new scientific discoveries and regulatory frameworks encouraging rare disease research. To capitalize on these opportunities, stakeholders should invest in partnerships with academic institutions for research collaborations and leverage government incentives for orphan drug development.

However, the market faces limitations such as high research and development costs, the complexity of clinical trials for rare diseases, and challenges in patient recruitment due to the disease's low prevalence. Navigating regulatory pathways can also be difficult, given the stringent guidelines for demonstrating efficacy in small patient populations.

In terms of innovation, the best areas to explore include gene editing technologies, such as CRISPR, and developing biomarkers for early diagnosis. Additionally, AI-driven analytics could revolutionize patient data analysis and trial optimization. The PFIC treatment market is inherently niche yet poised for rapid growth; ongoing transparency and collaboration among pharmaceutical companies, researchers, and healthcare providers are crucial for fostering innovation and addressing unmet medical needs effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Progressive Familial Intrahepatic Cholestasis Treatment Market

The Progressive Familial Intrahepatic Cholestasis Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing detection of progressive familial intrahepatic cholestasis with improvements in healthcare infrastructure
    • Expanding role of patient advocacy groups to expand PFIC treatments
  • Market Restraints
    • Access and affordability issues of PFIC treatments
  • Market Opportunities
    • Advancements in PFIC research and diagnostic technologies
    • Favorable government approvals for PFIC treatments
  • Market Challenges
    • Complexity in PFIC disease management and treatment efficacy

Porter's Five Forces: A Strategic Tool for Navigating the Progressive Familial Intrahepatic Cholestasis Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Progressive Familial Intrahepatic Cholestasis Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Progressive Familial Intrahepatic Cholestasis Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Progressive Familial Intrahepatic Cholestasis Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Progressive Familial Intrahepatic Cholestasis Treatment Market

A detailed market share analysis in the Progressive Familial Intrahepatic Cholestasis Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Progressive Familial Intrahepatic Cholestasis Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Progressive Familial Intrahepatic Cholestasis Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Progressive Familial Intrahepatic Cholestasis Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Calliditas Therapeutics AB, CANbridge Pharmaceuticals Inc., Centurion Laboratories Private Limited, CymaBay Therapeutics, Inc., Enomark, Glenmark Pharmaceuticals Limited, Healthy Life Pharma Pvt. Ltd., Hebei Xingang Pharmaceutical Co., Ltd., Intercept Pharmaceuticals, Inc., Ipsen Pharma, Jackson Laboratories Pvt Ltd., Macleods Pharmaceuticals Ltd., Mirum Pharmaceuticals, Inc., Novartis AG, Par Pharmaceuticals, Inc. by Endo International PLC, Pfizer Inc., Sanofi S.A., SiNi Pharma Pvt. Ltd., Taj Pharmaceuticals Limited, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Viatris Inc., Vivet Therapeutics, Wellona Pharma, and Zoic Biotech Pvt. Ltd..

Market Segmentation & Coverage

This research report categorizes the Progressive Familial Intrahepatic Cholestasis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Cholestyramine, Rifampicin, and Ursodeoxycholic Acid.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on End-Users, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing detection of progressive familial intrahepatic cholestasis with improvements in healthcare infrastructure
      • 5.1.1.2. Expanding role of patient advocacy groups to expand PFIC treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Access and affordability issues of PFIC treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in PFIC research and diagnostic technologies
      • 5.1.3.2. Favorable government approvals for PFIC treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity in PFIC disease management and treatment efficacy
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Rising usage of cholestyramine for reducing the level of bile acids in the liver and blood
    • 5.2.2. Distribution Channel: Preference for online pharmacies for continuous and convenient access to prescribed medications.
    • 5.2.3. End-Users: High potential for PFIC treatments in hospitals to manage severe complications of PFIC
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Cholestyramine
  • 6.3. Rifampicin
  • 6.4. Ursodeoxycholic Acid

7. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Online Pharmacies
  • 7.4. Retail Pharmacies

8. Progressive Familial Intrahepatic Cholestasis Treatment Market, by End-Users

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Americas Progressive Familial Intrahepatic Cholestasis Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Progressive Familial Intrahepatic Cholestasis Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Progressive Familial Intrahepatic Cholestasis Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. FDA Endorses Livmarli for Pruritus Management in Progressive Familial Intrahepatic Cholestasis Patients
    • 12.3.2. Canadian Government Allocates CAD 20 Million to Enhance Health Outcomes for Children with Rare Diseases, Including Progressive Familial Intrahepatic Cholestasis
    • 12.3.3. French Government Awards Euro 4.9 Million Grant for Innovative Gene Therapy Development by Vivet Therapeutics"
    • 12.3.4. Approval of Bylvay (odevixibat) by Health Canada for PFIC-Related Pruritus
    • 12.3.5. CANbridge Pharmaceuticals Gains NMPA Approval for CAN108 NDA
    • 12.3.6. UKRI Allocates GBP 14 Million to Advance Research on Progressive Familial Intrahepatic Cholestasis and Other Rare Diseases
    • 12.3.7. Jadeite Medicines Advances Treatment for PFIC with Phase 3 Trial and Orphan Drug Designation in Japan
    • 12.3.8. India Boosts Rare Diseases Treatment, Allocates INR 40 Crore with a Focus on PFIC and Enhanced Patient Care
    • 12.3.9. Ipsen Enhances Rare Disease Offerings with Strategic Acquisition of Albireo Pharma

Companies Mentioned

  • 1. AbbVie, Inc.
  • 2. Calliditas Therapeutics AB
  • 3. CANbridge Pharmaceuticals Inc.
  • 4. Centurion Laboratories Private Limited
  • 5. CymaBay Therapeutics, Inc.
  • 6. Enomark
  • 7. Glenmark Pharmaceuticals Limited
  • 8. Healthy Life Pharma Pvt. Ltd.
  • 9. Hebei Xingang Pharmaceutical Co., Ltd.
  • 10. Intercept Pharmaceuticals, Inc.
  • 11. Ipsen Pharma
  • 12. Jackson Laboratories Pvt Ltd.
  • 13. Macleods Pharmaceuticals Ltd.
  • 14. Mirum Pharmaceuticals, Inc.
  • 15. Novartis AG
  • 16. Par Pharmaceuticals, Inc. by Endo International PLC
  • 17. Pfizer Inc.
  • 18. Sanofi S.A.
  • 19. SiNi Pharma Pvt. Ltd.
  • 20. Taj Pharmaceuticals Limited
  • 21. Takeda Pharmaceutical Company Limited
  • 22. Teva Pharmaceutical Industries Ltd.
  • 23. Viatris Inc.
  • 24. Vivet Therapeutics
  • 25. Wellona Pharma
  • 26. Zoic Biotech Pvt. Ltd.

LIST OF FIGURES

  • FIGURE 1. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2018-2030 (USD THOUSAND)
  • FIGURE 4. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 5. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 6. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 8. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 10. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 12. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 14. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 16. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 20. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2018-2030 (USD THOUSAND)
  • TABLE 4. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 5. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 6. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 8. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 9. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RIFAMPICIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 10. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 11. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 12. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 13. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 14. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 15. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 16. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 17. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 18. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 19. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 20. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 21. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 22. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 23. ARGENTINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 24. ARGENTINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 25. ARGENTINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 26. BRAZIL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 27. BRAZIL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 28. BRAZIL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 29. CANADA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 30. CANADA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 31. CANADA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 32. MEXICO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 33. MEXICO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 34. MEXICO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 35. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 36. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 37. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 38. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD THOUSAND)
  • TABLE 39. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 40. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 41. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 42. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 43. AUSTRALIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 44. AUSTRALIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 45. AUSTRALIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 46. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 47. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 48. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 49. INDIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 50. INDIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 51. INDIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 52. INDONESIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 53. INDONESIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 54. INDONESIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 55. JAPAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 56. JAPAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 57. JAPAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 58. MALAYSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 59. MALAYSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 60. MALAYSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 61. PHILIPPINES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 62. PHILIPPINES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 63. PHILIPPINES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 64. SINGAPORE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 65. SINGAPORE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 66. SINGAPORE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 67. SOUTH KOREA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 68. SOUTH KOREA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 69. SOUTH KOREA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 70. TAIWAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 71. TAIWAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 72. TAIWAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 73. THAILAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 74. THAILAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 75. THAILAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 76. VIETNAM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 77. VIETNAM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 78. VIETNAM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 83. DENMARK PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 84. DENMARK PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 85. DENMARK PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 86. EGYPT PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 87. EGYPT PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 88. EGYPT PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 89. FINLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 90. FINLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 91. FINLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 92. FRANCE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 93. FRANCE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 94. FRANCE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 95. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 96. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 97. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 98. ISRAEL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 99. ISRAEL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 100. ISRAEL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 101. ITALY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 102. ITALY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 103. ITALY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 104. NETHERLANDS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 105. NETHERLANDS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 106. NETHERLANDS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 107. NIGERIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 108. NIGERIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 109. NIGERIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 110. NORWAY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 111. NORWAY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 112. NORWAY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 113. POLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 114. POLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 115. POLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 116. QATAR PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 117. QATAR PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 118. QATAR PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 119. RUSSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 120. RUSSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 121. RUSSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 122. SAUDI ARABIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 123. SAUDI ARABIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 124. SAUDI ARABIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 125. SOUTH AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 126. SOUTH AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 127. SOUTH AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 128. SPAIN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 129. SPAIN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 130. SPAIN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 131. SWEDEN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 132. SWEDEN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 133. SWEDEN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 134. SWITZERLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 135. SWITZERLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 136. SWITZERLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 137. TURKEY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 138. TURKEY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 139. TURKEY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 140. UNITED ARAB EMIRATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 141. UNITED ARAB EMIRATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 142. UNITED ARAB EMIRATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 143. UNITED KINGDOM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 144. UNITED KINGDOM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 145. UNITED KINGDOM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
  • TABLE 146. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023